Retraction notice to “MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC)” [Biomed. Pharmacother. 76 (2015) 82–93]

• Yu Mao,
• Jia Liu,
• Dakai Zhang,
• Baosheng Li

Affiliations

Yu Mao

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China

Jia Liu

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China; School of Medicine and Life Sciences, University of Jinan—Shandong Academy of Medical Sciences, Jinan, China

Dakai Zhang

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China; School of Medicine and Life Sciences, University of Jinan—Shandong Academy of Medical Sciences, Jinan, China

Baosheng Li

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China; Corresponding author.